TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03841942

Intervention type: OTHER
Group type: OTHER
Intervention: clinically-based spacing strategy
Description: All patients (as there are free from symptoms) will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission is maintained (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC), patients will have a second step of a 2 weeks infliximab infusion spacing which will be maintained until the end of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Trough level-based strategy
Description: patients will have at inclusion a determination of the infliximab trough level. According to this dosage, only patients with a trough level ≥ 7 µg/ml will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC) is maintained and if infliximab trough level is still ≥ 7 ug/ml, patients will have a second step of 2 weeks infliximab spacing until the end of the study.~Patients with a baseline infliximab trough level \< 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study.
Study: NCT02844985

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Study: NCT01419119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol high dose at Vitamin D deficiency
Description: 10 000 IU daily i.e. 15 drops orally once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol median dose at Vitamin D insufficiency
Description: 2000 IU daily i.e. 3 drops orally once a day for 12 weeks,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol low dose at Vitamin D deficiency
Description: 2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol median dose at sufficient Vitamin D level
Description: 2000 IU daily i.e. 3 drops orally once daily for 12 weeks
Study: NCT04851002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of advanced platelet rich fibrin with dental implants
Description: Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity also A-PRF membrane covered socket and implant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control side of concentrated growth factor study group
Description: Traditional implant methods applied
Study: NCT02625181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated recommendation at the start of the case
Description: The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
Study: NCT04851002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control side of advanced platelet rich fibrin study group
Description: Traditional implant methods applied
Study: NCT05101395

Intervention type: OTHER
Intervention: Giemsa stain
Description: Giemsa special stain was employed for detection of H. Pylori microorganisms.
Study: NCT03400215

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Breast Cancer Scan
Description: clinically indicated diagnostic breast MRI scans
Study: NCT02625181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated notification at the start of surgery
Description: The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative recommendations: by email
Description: A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated notification at the end of surgery
Description: A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
Study: NCT03400215

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Breast Cancer Scan
Description: clinically indicated diagnostic breast MRI scans

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Research Scan for Gradient-echo Spectroscopic Imaging (GSI)
Description: 15-min research MRI scan

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Research Scan for Gradient-echo Spectroscopic Imaging (GSI)
Description: 15-min research MRI scan
Study: NCT02625181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anesthesia Information Management System (AIMS)
Description: The anesthesia electronic record keeping system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perioperative Data Warehouse (PDW)
Description: The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective surgery
Description: Surgical procedures that are scheduled and not an emergency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Prophylactic antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol
Description: Prophylactic antiemetic \& rescue antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Prophylactic antiemetic \& rescue antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Prophylactic antiemetic \& rescue antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: Prophylactic antiemetic \& rescue antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine
Description: Prophylactic antiemetic \& rescue antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Prophylactic antiemetic \& rescue antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Rescue antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Analgesic drug / Opioid
Study: NCT01047748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-fetal digoxin injection
Description: Single transabdominal injection of digoxin 1 mg into the fetus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-amniotic digoxin injection
Description: Single transabdominal injection of digoxin 1 mg into the amniotic fluid
Study: NCT03823599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile chat-based instant messages
Description: Subjects in the active arm study will receive 5-minute face-to-face ABI, alcohol leaflet from Department of Health (DH) plus continuous interactive chat-based intervention for 1 month as an extension of alcohol brief intervention at baseline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol brief intervention
Description: The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol brief intervention
Description: The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.
Study: NCT00709917

Intervention type: DRUG
Intervention: repaglinide
Description: Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
Study: NCT01025011

Intervention type: DEVICE
Intervention: Fundus photography, cubital blood draw
Description: blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
Study: NCT02451202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Neuromuscular Blockade
Description: * During maintenance phase, if recovery after 1 Post-Tetanic-count (PTC) responses, a continuous infusion can be initiated to maintain deep NMB (TOF =0, PTC 1-2).~* At the end of surgery, continuous infusion Rocuronium and Propofol are discontinued and paralysis will be simultaneously reversed by Sugammadex 4mg/kg from PTC 1-2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Neuromuscular Blockade
Description: - During maintenance phase, if recovery at the presence of \<10% of control T1 of TOF from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain TOF = 1 - 2. The initial pump rate will be set at 0.5 mg/kg per hour.
Study: NCT02625181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Analgesic drug / Opioid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: Analgesic drug / Opioid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Analgesic drug / Opioid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Analgesic drug / Opioid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine
Description: Analgesic drug / Opioid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Analgesic drug / Opioid
Study: NCT02451202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Study: NCT02625181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Analgesic drug / Opioid
Study: NCT02451202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study: NCT01303432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt supplemented with Mobilee
Description: One yogurt (125mL) per day including 80mg of Mobilee
Study: NCT02625181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Analgesic drug / Opioid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone
Description: Analgesic drug / Opioid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone
Description: Analgesic drug / Opioid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Analgetic / Analgesic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Prophylactic antiemetic \& rescue antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Prophylactic antiemetic \& rescue antiemetic
Study: NCT01303432

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt
Description: One yogurt (125mL) per day
Study: NCT03555240

Intervention type: OTHER
Intervention: Biobank creation and Pharmacogenetic analysis
Description: Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
Study: NCT01230749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
Study: NCT04437030

Intervention type: DEVICE
Group type: OTHER
Intervention: MSOT Acuity Echo device
Description: The MSOT acutiy Echo device can take ultrasound recordings in addition to photoacoustic recordings.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MSOT Acuity Echo device
Description: The MSOT acutiy Echo device can take ultrasound recordings in addition to photoacoustic recordings.
Study: NCT01279304

Intervention type: RADIATION
Intervention: radiation - no radiation see intervention description
Description: after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)

Intervention type: RADIATION
Intervention: radiation: see intervention description
Description: after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.

Intervention type: RADIATION
Intervention: radiation: see intervention description
Description: after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
Study: NCT05113719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will perform bridge exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will perform bridge exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will perform bridge exercise
Study: NCT02625181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate
Description: Prophylactic antiemetic \& rescue antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Prophylactic antiemetic \& rescue antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropisetron
Description: Prophylactic antiemetic \& rescue antiemetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Prophylactic antiemetic \& rescue antiemetic
Study: NCT00839423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets, daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets, daily, orally

Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine XL
Description: capsules, daily, orally
Study: NCT01234493

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation
Description: Syndesmosis fixation with one 3.5mm fully threaded three cortical screw

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no fixation
Description: No syndesmosis fixation.
Study: NCT00953641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure
Study: NCT01862081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
Study: NCT00953641

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy
Study: NCT01862081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel 80 mg/m\^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel 80 mg/m\^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel 80 mg/m\^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
Study: NCT01519401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 mg drospirenone and 20 µg ethinyl-estradiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 mg drospirenone and 30 µg ethinyl-estradiol
Study: NCT00326222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Self-management group education
Study: NCT04742049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based
Description: 15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. Online exercise training protocol will be apply for patients. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks with a physiotherapist. Exercise protocol will start with the warm-up exercises and finish with cooling exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up based
Description: 15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. An exercise document including the same exercise protocol in study group will be sent the patients. Patients will be called by the physiotherapist once a week for follow-up. .
Study: NCT02003729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Sleep Monitor
Description: ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.